ABVC - ABVC Biopharma Stock Price, Fair Value and News

1.15USD+0.02 (+1.77%)Market Closed

Market Summary

USD1.15+0.02

Market Closed

1.77%

ABVC Stock Price

View Fullscreen

ABVC RSI Chart

ABVC Valuation

Market Cap

12.1M

Price/Earnings (Trailing)

-1.15

Price/Sales (Trailing)

79.67

EV/EBITDA

-1.49

Price/Free Cashflow

-2.85

ABVC Price/Sales (Trailing)

ABVC Profitability

Operating Margin

-98.15%

EBT Margin

-6989.62%

Return on Equity

-125.36%

Return on Assets

-72.56%

Free Cashflow Yield

-35.05%

ABVC Fundamentals

ABVC Revenue

Revenue (TTM)

152.4K

Rev. Growth (Yr)

-99.63%

Rev. Growth (Qtr)

-86.37%

ABVC Earnings

Earnings (TTM)

-10.5M

Earnings Growth (Yr)

36.04%

Earnings Growth (Qtr)

6.23%

Breaking Down ABVC Revenue

Last 7 days

-27.7%

Last 30 days

-10.8%

Last 90 days

-23.3%

Trailing 12 Months

-84.2%

How does ABVC drawdown profile look like?

ABVC Financial Health

Current Ratio

0.28

ABVC Investor Care

Shares Dilution (1Y)

141.63%

Diluted EPS (TTM)

-2.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.1M	765.6K	739.3K	152.4K
2022	0	0	0	969.8K
2021	0	0	0	0
2020	568.3K	0	0	0
2019	470.0K	547.3K	624.5K	701.7K
2018	0	238.3K	315.6K	392.8K
2017	71.1K	161.1K	0	0
2016	0	0	0	73.4K
2015	3.0K	2.3K	3.4K	0
2013	26.9K	7.8K	7.8K	0
2012	0	0	24.9K	29.9K
2011	0	0	0	0
2010	0	0	434.1K	0

Get all data in R, Python etc through our Historical Stock Data APIs

Which funds bought or sold ABVC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	48.72	12,553	31,607	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-21,000	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	added	74.19	15,288	31,503	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 13, 2024	RENAISSANCE TECHNOLOGIES LLC	new	-	42,000	42,000	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	2,337	22,596	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	reduced	-80.64	-2,434	670	-%
Feb 12, 2024	JPMORGAN CHASE & CO	sold off	-100	-2.00	-	-%
Feb 09, 2024	WELLS FARGO & COMPANY/MN	added	11.11	4.00	23.00	-%

Are Funds Buying or Selling ABVC?

Are funds buying ABVC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABVC

No. of Funds

Unveiling ABVC Biopharma's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	lind global fund ii lp	9.9%	770,000	SC 13G/A
Aug 07, 2023	lind global fund ii lp	9.9%	385,000	SC 13G
Jul 12, 2022	jiang shuling	24.5%	7,908,805	SC 13D

Recent SEC filings of ABVC Biopharma

View All Filings

Date Filed	Form Type	Document
Apr 30, 2024	EFFECT	EFFECT
Apr 26, 2024	PRE 14A	PRE 14A
Apr 25, 2024	POS AM	POS AM
Apr 19, 2024	8-K	Current Report
Apr 17, 2024	8-K	Current Report
Apr 05, 2024	424B4	Prospectus Filed
Apr 01, 2024	EFFECT	EFFECT
Mar 29, 2024	CORRESP	CORRESP
Mar 26, 2024	8-K	Current Report
Mar 25, 2024	DEFA14A	DEFA14A

Peers (Alternatives to ABVC Biopharma)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

ABVC Biopharma News

Latest updates

ABVC Biopharma Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-86.4%	2,165	15,884	6,109	128,272	588,994	42,269	312,860	25,660	13,430	1,200	29,788	58,377	86,965	115,553	97,170	78,786	99,962	197,733	191,782	212,242	181,682
Cost Of Revenue	370.1%	139,206	29,614	72,981	60,236	265,411	10,741	8,367	1,896	2,802	393	646	1,245	1,902	8,619	4,236	3,959	2,489	2,797	13,352	1,499	182,424
Gross Profit	-898.1%	-137,041	-13,730	-66,872	68,036	323,583	31,528	304,493	23,764	-40,595	98,606	30,795	261,905	60,291	106,934	222,277	74,827	97,473	194,936	178,430	210,743	-224,444
Operating Expenses	-14.8%	1,824,569	2,141,143	2,126,970	1,974,220	3,456,573	3,747,369	2,351,353	6,242,485	6,406,559	2,069,160	2,066,310	1,514,650	4,910,911	1,396,700	1,416,290	1,246,204	1,221,256	1,310,558	667,238	941,309	1,010,203
S&GA Expenses	29.1%	1,526,645	1,182,093	1,386,788	1,272,752	67,490	3,216,146	1,592,831	1,191,078	1,766,836	1,579,996	1,231,692	1,167,595	1,080,857	1,262,199	1,277,133	1,152,889	937,528	1,041,319	571,669	510,803	375,405
R&D Expenses	-48.9%	72,185	141,310	514,442	334,979	1,495,788	305,483	532,782	359,404	260,188	263,424	358,878	121,315	183,285	134,501	139,082	92,790	269,589	269,239	87,769	421,956	629,399
EBITDA Margin	-8.3%	-53.35	-49.27	-22.44	-21.37	-26.74	-31.17	-28.14	-28.17	-19.31	-17.58	-17.99	-18.09	-18.25	-	-	-	-	-	-	-	-
Interest Expenses	-9.5%	1,103,301	1,218,624	114,752	56,663	134,461	126,536	14,758	18,213	-24,367	38,677	82,671	130,229	116,679	16,311	140,525	131,517	107,474	111,968	132,686	129,886	116,769
Income Taxes	17648.5%	175,310	-999	81,695	-	962,874	4,222	-82,451	-86,867	1,011,279	-75,667	-59,564	-51,024	-86,405	-44,735	-48,644	-40,568	-27,253	48,555	-40,798	-57,545	-124,855
Earnings Before Taxes	6.4%	-3,154,443	-3,369,079	-2,233,530	-1,897,230	-3,538,028	-3,772,302	-2,029,784	-6,174,482	-5,890,049	-1,961,911	-2,112,520	-1,246,347	-5,055,539	-2,175,866	-2,232,701	-1,349,830	-1,143,038	-1,281,130	-655,251	-930,862	-4,052,423
EBT Margin	-21.9%	-69.90	-57.33	-23.37	-22.07	-27.30	-31.44	-28.25	-28.40	-19.73	-18.26	-18.64	-18.85	-19.03	-	-	-	-	-	-	-	-
Net Income	6.2%	-3,110,934	-3,317,516	-2,263,511	-1,823,695	-4,863,938	-3,704,864	-1,858,997	-5,995,440	-7,858,150	-1,806,488	-2,052,956	-1,195,323	-4,969,134	-2,131,131	-2,184,057	-1,309,262	-1,115,785	-1,329,685	-614,453	-873,317	-3,927,568
Net Income Margin	-8.3%	-68.99	-63.72	-25.85	-24.07	-28.90	-34.17	-30.83	-31.17	-22.72	-17.64	-18.21	-18.44	-18.64	-	-	-	-	-	-	-	-
Free Cashflow	-Infinity%	-479,460	-	-899,916	-1,497,722	-461,158	-518,061	-3,451,387	-3,087,477	-2,524,616	-2,216,025	-1,444,004	-1,413,074	-2,188,046	-328,802	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.7%	14,493	16,592	9,320	10,735	9,580	10,481	13,783	12,067	13,698	12,355	8,945	10,526	11,607	6,529	6,432	6,665	6,928	7,405	7,140	7,450	5,940
Current Assets	-33.6%	1,657	2,494	2,129	3,480	2,987	2,903	9,789	7,988	7,654	7,111	3,628	5,205	6,173	1,178	1,605	802	878	1,708	1,234	1,527	566
Cash Equivalents	-94.6%	60.00	1,121	99.00	1,135	85.00	1,970	3,599	3,433	6,565	4,450	1,657	3,333	5,001	152	406	140	160	1,052	556	997	243
Inventory	-	-	-	-	-	-	20.00	22.00	23.00	26.00	60.00	-	-	-	-	-	-	-	-	258*	521*	1.00
Net PPE	0.2%	7,969	7,954	564	572	574	567	597	599	526	528	512	505	515	506	508	505	521	514	529	548	510
Liabilities	-15.5%	6,362	7,530	9,687	9,000	6,343	4,787	4,602	4,705	4,828	4,765	8,429	8,797	8,945	7,721	7,876	7,837	7,053	6,675	10,282	12,977	11,281
Current Liabilities	10.6%	5,932	5,363	5,773	5,075	5,544	3,894	3,646	3,664	3,692	3,439	4,376	4,666	4,844	6,046	7,574	7,655	6,814	5,878	10,108	12,435	10,988
Short Term Borrowings	5.5%	899	853	-	-	1,894	-	-	-	1,640	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-7.8%	8,388	9,100	1,362	1,670	3,099	5,693	9,181	7,361	8,870	7,590	516	1,729	2,662	-	-	-	-	730	-	-	-
Retained Earnings	-5.0%	-65,420	-62,309	-58,991	-56,728	-54,904	-50,040	-46,335	-44,476	-38,481	-30,548	-28,742	-26,770	-25,642	-20,794	-18,948	-17,098	-15,851	-14,773	-13,558	-13,001	-12,209
Additional Paid-In Capital	2.4%	82,637	80,662	68,078	68,048	67,937	66,494	66,240	62,579	58,114	49,716	41,002	40,752	40,752	29,949	28,223	28,223	28,180	28,180	18,688	15,681	14,984
Accumulated Depreciation	-	3,335	-	-	-	3,304	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	64.6%	7,940	4,823	3,308	3,308	3,286	3,120	3,131	2,968	2,505	2,688	2,442	2,442	2,442	-	-	-	-	-	-	-	-
Minority Interest	-571.9%	-257	-38.26	12.00	64.00	138	-225	-153	-65.49	27.00	-1,004	-924	-843	-776	-655	-370	-35.58	26.00	64.00	179	236	318
Float	-	-	-	5,200	-	-	-	18,852	-	-	-	16,488	-	-	-	73,262	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	64.7%	-479	-1,358	-899	-1,497	-461	-513	-3,429	-2,994	-2,524	-2,216	-1,444	-1,413	-2,188	-328	-1,416	-630	-1,495	-242	-796	-599	268
Share Based Compensation	-72.4%	226	818	226	366	1,893	226	226	4,692	4,380	226	476	226	3,147	999	75*	525*	-167	6.00	8.00	9.00	5.00
Cashflow From Investing	309.0%	154	-73.78	-	-	-83.29	-1,523	-22.03	-93.22	427	-810	-140	-281	107	-365	-	-	-218*	-14.10	-3.17	-17.80	-470
Cashflow From Financing	-94.7%	87.00	1,657	-31.59	2,207	-253	604	-	-	4,253	5,817	-116	42.00	6,869	444	1,645	610	604	752	358	1,374	230

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ABVC Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Income Statement [Abstract]

Revenues

$ 152,430

$ 969,783

Cost of revenues

302,037

286,415

Gross (loss) profit

(149,607)

683,368

Operating expenses

Selling, general and administrative expenses

5,368,278

6,067,545

Research and development expenses

1,062,916

2,693,457

Stock-based compensation

1,635,708

7,036,778

Total operating expenses

8,066,902

15,797,780

Loss from operations

(8,216,509)

(15,114,412)

Other income (expense)

Interest income

185,481

187,817

Interest expense

(2,493,340)

(293,968)

Operating sublease income

65,900

107,150

Impairment loss

(110,125)

Investment loss

(7,446)

Gain (loss) on foreign exchange changes

22,690

(259,463)

Loss on investment in equity securities

(221,888)

Other income (expenses)

3,384

(24,149)

Total other income (expenses)

(2,437,773)

(400,184)

Loss before provision income tax

(10,654,282)

(15,514,596)

Provision for income tax expense

256,006

797,778

Net loss

(10,910,288)

(16,312,374)

Net loss attributable to noncontrolling interests

(394,632)

110,865

Net loss attributed to ABVC and subsidiaries

(10,515,656)

(16,423,239)

Foreign currency translation adjustment

(741)

(22,532)

Comprehensive loss

$ (10,516,397)

$ (16,445,771)

Net loss per share:

Basic (in Dollars per share)

$ (2.43)

$ (5.19)

Weighted average number of common shares outstanding(1):

Basic (in Shares)

^[1]

4,335,650

3,166,460

[1]	Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.

ABVC Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)

Dec. 31, 2023

Dec. 31, 2022

Current Assets

Cash and cash equivalents

$ 60,155

$ 85,265

Restricted cash

656,625

1,306,463

Accounts receivable, net

1,530

98,325

Short-term investments

79,312

75,797

Prepaid expense and other current assets

101,051

150,235

Total Current Assets

1,656,709

2,987,247

Property and equipment, net

7,969,278

573,978

Operating lease right-of-use assets

809,283

1,161,141

Long-term investments

2,527,740

842,070

Deferred tax assets, net

117,110

Prepaid expenses – non-current

78,789

135,135

Security deposits

62,442

58,838

Prepayment for long-term investments

1,274,842

2,838,578

Due from related parties – non-current, net

113,516

865,477

Total Assets

14,492,599

9,579,574

Current Liabilities

Short-term bank loans

899,250

1,893,750

Accrued expenses and other current liabilities

3,696,380

2,909,587

Contract liabilities

79,500

10,985

Taxes payables

112,946

Operating lease liabilities – current portion

401,826

369,314

Due to related parties

173,132

359,992

Convertible notes payable – third parties, net

569,456

Total Current Liabilities

5,932,490

5,543,628

Tenant security deposit

21,680

7,980

Operating lease liability – non-current portion

407,457

791,827

Total Liabilities

6,361,627

6,343,435

COMMITMENTS AND CONTINGENCIES

Equity

Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding

Common stock, $0.001 par value, 100,000,000 authorized, 7,940,298 and 3,286,190 shares issued and outstanding as of December 31, 2023 and 2022, respectively(1)

^[1]

7,940

3,286

Additional paid-in capital

82,636,966

67,937,050

Stock subscription receivable

(451,480)

(1,354,440)

Accumulated deficit

(65,420,095)

(54,904,439)

Accumulated other comprehensive income

516,387

517,128

Treasury stock

(8,901,668)

(9,100,000)

Total Stockholders’ equity

8,388,050

3,098,585

Noncontrolling interest

(257,078)

137,554

Total Equity

8,130,972

3,236,139

Total Liabilities and Equity

14,492,599

9,579,574

Related Party

Current Assets

Accounts receivable – related parties, net

10,463

757,343

Due from related parties – current

747,573

513,819

Due from related parties – non-current, net

113,516

865,477

Current Liabilities

Due to related parties

$ 173,132

$ 359,992

[1]	Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.

About ABVC Biopharma

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

WEBSITE	abvcpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	19

ABVC Biopharma Frequently Asked Questions

What is the ticker symbol for ABVC Biopharma? What does ABVC stand for in stocks?

ABVC is the stock ticker symbol of ABVC Biopharma. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ABVC Biopharma (ABVC)?

As of Thu May 02 2024, market cap of ABVC Biopharma is 12.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABVC stock?

You can check ABVC's fair value in chart for subscribers.

What is the fair value of ABVC stock?

You can check ABVC's fair value in chart for subscribers. The fair value of ABVC Biopharma is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ABVC Biopharma is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABVC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ABVC Biopharma a good stock to buy?

The fair value guage provides a quick view whether ABVC is over valued or under valued. Whether ABVC Biopharma is cheap or expensive depends on the assumptions which impact ABVC Biopharma's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABVC.

What is ABVC Biopharma's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, ABVC's PE ratio (Price to Earnings) is -1.15 and Price to Sales (PS) ratio is 79.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABVC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ABVC Biopharma's stock?

In the past 10 years, ABVC Biopharma has provided -0.539 (multiply by 100 for percentage) rate of return.